Open AccessIDH 2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer
Author(s) -
Li Jiangjiang,
Li Ruilei,
Wang Wenxiang,
Zhang Baihua,
Song Xin,
Zhang Chunfang,
Gao Yang,
Liao Qianjin,
He Ya,
You Shuo,
Tan Zheqiong,
Luo Xiangjian,
Li Yueshuo,
Tang Min,
Weng Xinxian,
Yi Wei,
Peng Shifang,
Liu Shaohui,
Tan Ying,
Bode Ann M.,
Cao Ya
Publication year - 2018
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12182
Subject(s) - lung cancer , biomarker , oncology , medicine , confidence interval , survival analysis , biology , biochemistry
Lung cancer is the most common leading cause of cancer‐related death worldwide. Late diagnosis contributes to a high mortality rate and poor survival of this cancer. In our previous study, we found that IDH 2 polymorphism rs11540478 is a risk factor for lung cancer. Here, we examined IDH 2 protein expression in culture medium in which two non‐small‐cell lung cancer ( NSCLC ) cell lines, H460 and A549, were growing. We found that the IDH 2 protein was elevated in the culture supernatant fraction in a time‐ and cell number‐dependent manner. Next, we used ELISA methods to examine IDH 2 protein level in serum from patients with NSCLC and healthy controls. We found that IDH 2 protein levels in serum could distinguish NSCLC patients from healthy controls with an AUC (area under the curve) of 0.83 (95% confidence interval = 0.79–0.88). The IDH 2 level was decreased in serum from NSCLC postsurgical patients compared with the paired presurgical serum. High s erum IDH 2 levels appear to correlate with poor survival in patients with NSCLC . These results suggest that IDH 2 levels in the serum could be a new effective biomarker for the diagnosis and prognosis of NSCLC .